Research
Participant demographics (unweighted counts).
OPAL (Open@LaTrobe) (La Trobe University) – May 07, 2025
Summary
Psilocybin's potential to reduce opioid use disorder (OUD) odds varies significantly across racial and ethnic groups. Analyzing 706,891 individuals' national survey data in a cross-sectional study via logistic regression revealed a clear association with lower odds only for White (0.84 odds ratio) and Hispanic (0.68 odds ratio) participants. Black, Asian, Indigenous, and Multiracial ethnic groups showed no such link. This highlights crucial demographic differences in the medicine's psychological impact, informing clinical psychology and psychiatry.
Abstract
Background: Opioid use disorder (OUD) is a debilitating health condition that is associated with significant morbidity and mortality in the U.S. Wh...
Psychedelic-assisted psychotherapy and its potential to manage demoralization: A brief exploration of an alternative approach to end of life care
OpenAlex – May 07, 2025
Summary
Australia has made a landmark decision in Medicine, becoming the first country to approve specific psychedelics for clinical use. Psychotherapists can consider MDMA for post-traumatic stress disorder and psilocybin for treatment-resistant depression, a significant step in Psychology. This move opens new avenues in Psychedelics and Drug Studies. Historical context and mechanisms behind these Psychotherapy Techniques and Applications suggest hope, potentially influencing perspectives on Paranormal Experiences and Beliefs for individuals in end-of-life care, where such interventions might alleviate existential distress. This development could reshape therapeutic approaches.
Abstract
Australia has become the first country to approve the use of psychedelics, namely MDMA and psilocybin, for clinical treatment of post-traumatic str...
Participant demographics (weighted %).
OPAL (Open@LaTrobe) (La Trobe University) – May 07, 2025
Summary
Psilocybin's association with lower opioid use disorder odds varies significantly by ethnic group. A large demography analysis of 706,891 individuals from the National Survey on Drug Use and Health, using logistic regression, revealed White participants had 16% lower odds (aOR: 0.84) and Hispanic participants 32% lower odds (aOR: 0.68) of OUD with psilocybin use. No such association was found for Black, Asian, Indigenous, or Multiracial groups. This highlights crucial race-based disparities in medicine and clinical psychology, impacting psychiatry.
Abstract
Background: Opioid use disorder (OUD) is a debilitating health condition that is associated with significant morbidity and mortality in the U.S. Wh...
The Role of Touch in Psychedelic Therapy: Perspectives From a Survey of Practitioners in Research Settings.
American journal of psychotherapy – May 06, 2025
Summary
Physical touch during psychedelic therapy sessions can play a vital role in patient care, according to healthcare practitioners. While 70% of surveyed professionals view therapeutic touch as crucial during psilocybin and other psychedelic treatments, clear ethical boundaries are essential. Most support gentle contact like hand-holding, with explicit consent required. This balanced approach helps create a safe, supportive environment while maintaining professional standards.
Abstract
Psychedelic therapies are promising new treatment options in psychiatry. Including the use of physical touch as part of treatment is an area of deb...
Psilocybin Mitigates Behavioral Despair and Cognitive Impairment in Treatment-resistant Depression Model using Wistar Kyoto Rats
OpenAlex – May 06, 2025
Summary
Psilocybin dramatically improved severe depression and cognitive impairment in a recent preclinical study. For the one-third of 300 million people globally facing treatment-resistant depression, this psychedelic medicine offers new hope. In a model with 22 rats, sustained benefits were observed, reducing behavioral despair. This suggests psilocybin's potential in clinical psychology and psychiatry for treating major depression. Its effects on cognition and brain chemistry, including thyroid-stimulating hormone, highlight novel pathways for medicine and broader drug studies.
Abstract
Abstract Major depressive disorder (MDD) is a leading cause of disability that affects over 300 million people globally. Despite multiple antidepre...
Low-dose ketamine infusion to facilitate opioid tapering in chronic non-cancer pain with opioid-use disorder: a historical cohort study.
Regional anesthesia and pain medicine – May 06, 2025
Summary
Low-dose ketamine shows promise in helping patients with chronic pain reduce their dependence on opioid analgesics. In a breakthrough finding, 68% of patients achieved a 50% reduction in opioid use after just 5 days of treatment. The study followed patients with opioid-related disorders who struggled to decrease their medication use through traditional methods. A brief hospital stay with ketamine infusion helped reduce daily opioid doses from 207mg to 92mg, with benefits lasting up to one year.
Abstract
Long-term opioid use is associated with pharmacological tolerance, a risk of misuse and hyperalgesia in patients with chronic pain (CP). Tapering i...
Realizing the Economic Potential of Meditation and Mindfulness Practices in Mental Health Care.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research – May 06, 2025
Summary
No Summary
Abstract
This commentary explores the economic potential of integrating meditation and mindfulness practices into mental health care, highlighting their cos...
New Psychoactive Substance Esketamine Causes Endocrine-Disrupting Effects and Developmental Toxicity.
Environmental science & technology – May 06, 2025
Summary
The hallucinogenic compound esketamine, found in waterways globally, shows concerning effects on aquatic life. Research using zebrafish revealed that this new psychoactive substance disrupts hormone systems and impacts early development. At certain levels, it altered growth patterns and interfered with crucial biological processes, including circadian rhythms and estrogen signaling pathways.
Abstract
Esketamine (ESK), a new psychoactive substance known for its strong hallucinogenic effect, has been detected in surface water worldwide. The toxici...
Vigilance state dissociation induced by 5-MeO DMT in mice
Research Square – May 06, 2025
Summary
A powerful psychedelic compound found in some plants can create a unique state where mice appear awake but show brain patterns typical of deep sleep. Scientists found that 5-MeO-DMT triggers this unusual "mixed state," where physical activity continues while brain waves slow dramatically. This discovery offers insights into consciousness and could help explain how psychedelics affect the brain.
Abstract
Vigilance state dissociation induced by 5-MeO DMT in mice
Microglial brain-derived neurotrophic factor (BDNF) supports the behavioral and synaptogenic effects of ketamine
bioRxiv Preprint Server – May 05, 2025
Summary
Brain immune cells, called microglia, are crucial for antidepressant effects. Research shows that ketamine's rapid positive impact on mood and brain function, specifically by increasing synaptic density in the prefrontal cortex, relies on brain-derived neurotrophic factor (BDNF) produced by these microglia. When microglial BDNF was available, ketamine successfully enhanced brain connections and improved antidepressant responses. This reveals a vital role for microglia in pharmacological interventions.
Abstract
Microglia have been implicated in the pathogenesis for several psychiatric disorders, yet comparatively little is known about their role in treatme...
Association of low-dose ketamine with hallucinations in critically ill patients: a target trial emulation.
Intensive care medicine – May 05, 2025
Summary
Low-dose ketamine, commonly used for pain relief and sedation in intensive care, increases hallucination risk by over 6 times in critically ill patients. Among 7,500+ patients studied, those receiving ketamine for analgesia experienced hallucinations much earlier and more frequently (26% vs 7%) than those who didn't. This important finding helps doctors better balance ketamine's benefits against its potential to trigger delirium and other side effects.
Abstract
Ketamine use is a potentially modifiable risk factor for hallucinations. We aimed to use target trial emulation to investigate the association betw...
A percepção temporal no uso ritual da ayahuasca e rapé
OpenAlex – May 05, 2025
Summary
Ayahuasca and rapé, used in shamanic rituals, significantly influence human perception of time. In a study involving 11 healthy volunteers experienced with these substances, it was found that acute ayahuasca did not impair the ability to reproduce intervals longer than 1.6 seconds. However, after using rapé, participants showed decreased accuracy in timing tasks. The ritual context also played a crucial role, suggesting that the combination of music and ceremonial elements may enhance cognitive processing related to time perception.
Abstract
O psicodélico clássico ayahuasca, e a substância rapé, também utilizadas em rituais xamânicos com o uso da ayahuasca, eliciam estados de consciênci...
Are the LSD-analogs lisuride and ergotamine examples of non-hallucinogenic serotonin 5-HT2A receptor agonists?
Journal of psychopharmacology (Oxford, England) – May 05, 2025
Summary
While LSD is famous for its psychedelic effects, scientists long believed some similar compounds could activate the same brain receptors without causing hallucinations. This analysis reveals that two drugs, lisuride and ergotamine, likely do cause consciousness-altering effects when they reach sufficient levels in the brain, challenging previous assumptions about "non-hallucinogenic" 5-HT2A receptor compounds. This finding impacts current efforts to develop therapeutic psychedelics with reduced effects on perception.
Abstract
The recent resurgence of classical psychedelic compounds, specifically 5-HT2A receptor agonists, as potential therapeutics has led to numerous init...
Robot-assisted gait training for individuals with severe acquired brain injury: a scoping review.
Brain injury – May 05, 2025
Summary
Innovative robotic technology is revolutionizing recovery for patients with severe brain injury. Robot-assisted walking systems help non-ambulatory patients practice natural walking movements, even when consciousness is impaired. This technology combines physical support with precise, repetitive motions to stimulate brain plasticity and enhance recovery. Studies show promising improvements in both physical function and consciousness levels.
Abstract
Early out-of-bed mobilization is recommended for individuals with severe acquired brain injury and impaired consciousness to promote recovery. Robo...
Selective preservation of prediction-related signals in human sleep.
Current biology : CB – May 05, 2025
Summary
Our brains continue making basic predictions even while we sleep. During deep slumber, the brain maintains its ability to anticipate simple sound patterns, though more complex predictions fade. Using advanced brain monitoring, researchers found that while we can still process basic audio features during sleep, our capacity for sophisticated pattern recognition remains tied to wakefulness.
Abstract
Imagine listening to a familiar song on the radio. As the melody unfolds, you often anticipate the following note or beat before it plays. This abi...
Ketamine evokes acute behavioral effects via μ-opioid receptor expressing neurons of the central amygdala.
Biological psychiatry – May 05, 2025
Summary
Ketamine's remarkable antidepressant effects may work through an unexpected pathway in the brain's emotional center. Scientists discovered that ketamine activates specific neurons in the central amygdala that contain mu opioid receptors. When these receptors were blocked with naltrexone, ketamine's effects diminished significantly. This finding explains why ketamine's antidepressant properties differ from similar medications and offers new insights into treating depression.
Abstract
Ketamine has anesthetic, analgesic, and antidepressant properties which may involve multiple neuromodulatory systems. In humans, the opioid recepto...
Role of CaMKII/CREB pathway in rapid-antidepressant-like effect: comparison of ketamine with rapastinel.
Experimental brain research – May 04, 2025
Summary
Breakthrough findings reveal how two promising depression treatments - ketamine and rapastinel - work through different brain pathways to combat chronic stress. While both drugs boost mood-related BDNF proteins, they interact differently with brain signaling systems. Ketamine requires CaMKII/CREB activation for its antidepressant effects, while rapastinel works better when this pathway is blocked, suggesting multiple routes to enhance synaptic plasticity and mood.
Abstract
Recent studies in mouse models have demonstrated that ketamine and rapastinel induce rapid-acting and sustained antidepressant effects in major dep...
"Big chunks of blank memory": complex trauma and dissociative body memory.
Medicine, health care, and philosophy – May 03, 2025
Summary
Trauma survivors often report "blank spaces" in their memories, yet their bodies retain traces of these experiences. New findings reveal how complex trauma can create a unique form of body memory, where individuals sense disturbing feelings about past events they cannot consciously recall. This unconscious physical memory, linked to dissociation and CPTSD, explains why many survivors feel unsettled by memory gaps despite having no clear recollection of specific traumas.
Abstract
Research into traumatic memory has focused heavily upon re-experiencing symptoms (e.g. flashbacks). Features predominantly associated with complex ...
Clade III Synthases Add Cyclic and Linear Terpenoids to the Psilocybe Metabolome
ChemBioChem – May 03, 2025
Summary
*Psilocybe* mushrooms, known in Psychedelics and Drug Studies, produce a much richer array of natural products than just psilocybin. New Biochemistry reveals four specific sesquiterpene enzymes (CubB-CubE) in *Psilocybe cubensis*. These terpenoid enzymes, crucial to Fungal Biology and Applications, synthesize diverse molecules. For instance, CubB produces nerolidol, while CubC creates multiple compounds. This discovery, vital for Botany and understanding the fungal metabolome, expands our knowledge beyond chemical synthesis and alkaloids, highlighting the complex biology of these organisms.
Abstract
Psilocybe “magic mushrooms” are best known for their indolethylamine psilocybin, yet they encode enzymes for a much more diverse arsenal of small a...
Attitudes and Perceptions of Portuguese Psychiatrists and Psychologists on the Clinical Use of Ketamine.
Acta medica portuguesa – May 02, 2025
Summary
Portuguese mental health professionals show cautious optimism about ketamine's potential in treating stubborn depression. In a nationwide survey, 59% of psychiatrists and psychologists expressed openness to using ketamine therapeutically, though only 36% felt well-informed about it. While psychiatrists showed more confidence in ketamine's treatment potential than psychologists, both groups want more training before using it with patients.
Abstract
Ketamine has garnered attention for its rapid efficacy in alleviating depressive symptoms in treatment-resistant depression, offering a novel mecha...
Dimensions of corvid consciousness.
Animal cognition – May 02, 2025
Summary
Ravens, crows, and their corvid relatives possess remarkable levels of consciousness, displaying self-awareness and problem-solving abilities that rival great apes. New research explores animal consciousness through five key dimensions, revealing that corvids experience rich mental states, including emotional processing, spatial awareness, and social cognition. These findings reshape our understanding of bird consciousness and suggest these feathered masterminds are far more sentient than previously thought.
Abstract
Corvids have long been a target of public fascination and of scientific attention, particularly in the study of animal minds. Using Birch et al.'s ...
When pain overwhelms the self: A phenomenological study of a new mode of suffering, based on adults' recollections of their worst pain episodes.
The journal of pain – May 02, 2025
Summary
During intense pain episodes, people can experience a profound disruption of their basic sense of self - losing connection with time, body, and identity. Through in-depth interviews with chronic pain patients, researchers uncovered how severe pain can create immediate suffering that transcends conscious thought. This qualitative study revealed that overwhelming pain can lead to dissociative states where sufferers feel dehumanized and disconnected from themselves.
Abstract
Suffering is a foundational yet understudied construct within the field of pain. There is general agreement that pain-related suffering involves di...
The effect of esketamine on postoperative anxiety and depression in patients with thyroid cancer: A randomized, double-blind, placebo-controlled, parallel-group trial.
Medicine – May 02, 2025
Summary
A single dose of esketamine during thyroid cancer surgery can significantly reduce postoperative anxiety and depression. This breakthrough finding shows how a well-timed medication can improve mental well-being after surgery. Patients who received esketamine showed lower affective symptoms, more stable vital signs during surgery, and fewer postoperative complications. The treatment works by boosting beneficial brain chemicals while reducing stress markers.
Abstract
This study aimed to investigate the effects of a single intravenous injection of esketamine during general anesthesia on postoperative anxiety and ...
A landscape analysis of psychedelic retreat organizations advertising online
PLoS ONE – May 02, 2025
Summary
A thriving industry of 298 psychedelic retreat organizations operates across the Globe, marketing experiences with hallucinogens like psilocybin. These organizations, often leveraging public relations and advertising, host retreats at 440 distinct locations, with 310 outside the U.S. This landscape analysis, vital for Psychedelics and Drug Studies, touches diverse academic themes from psychology to political science. Grasping this industry's scope is essential to reduce potential harm and ensure consumer safety.
Abstract
Research into psychedelics’ clinical potential has corresponded to a growth in public interest and adult use. One common pathway to accessing psych...
Assessing brain neuroplasticity: Surface morphometric analysis of cortical changes induced by Quadrato motor training.
Journal of anatomy – May 01, 2025
Summary
No Summary
Abstract
Morphological markers for brain plasticity are still lacking and their findings are challenged by the extreme variability of cortical brain surface...
Integrative medicine in breast cancer survivorship care.
Annals of palliative medicine – May 01, 2025
Summary
Combining conventional care with integrative medicine approaches helps 70% of breast cancer survivors better manage treatment side effects and improve recovery. Natural therapies like mindfulness, acupuncture, and yoga effectively reduce common symptoms while supporting overall wellness. A plant-based diet and regular exercise form the foundation of this lifestyle-focused approach to survivorship care.
Abstract
Integrative medicine use is prevalent among breast cancer survivors to improve lifestyle and manage symptoms associated with cancer or its treatmen...
The Awakening of the Newborn Human Infant and the Emergence of Consciousness.
Acta paediatrica (Oslo, Norway : 1992) – May 01, 2025
Summary
No Summary
Abstract
Consciousness develops gradually in the womb and after birth, rather than being an all or none phenomenon. A newborn infant is aroused and wakes up...
0391 Racial/Ethnic Differences in Psychedelic Use and Sleep Satisfaction: Preliminary Findings from the Herbal Heart Study
SLEEP – May 01, 2025
Summary
A surprising finding in psychology highlights a complex link between psychedelic use and sleep satisfaction. Among 200 young adults, particularly within the Hispanic/Latino ethnic group, consuming psychedelics was associated with significantly poorer sleep. For instance, 33.9% of Hispanic/Latino psychedelic users reported sleep dissatisfaction, compared to 17.2% of non-users. Psilocybin users in this group faced 9.2 times higher odds of dissatisfaction. This insight from drug studies informs future medicine, clinical psychology, and psychiatry, emphasizing tailored support for sleep health.
Abstract
Abstract Introduction Research on psychedelic use and sleep satisfaction remains unclear despite increased use. This study examines the psychedelic...
Data Sheet 1_Dose-dependent changes in global brain activity and functional connectivity following exposure to psilocybin: a BOLD MRI study in awake rats.pdf
OPAL (Open@LaTrobe) (La Trobe University) – May 01, 2025
Summary
Psilocybin, a potent hallucinogen, profoundly alters brain activity, yet its effects in awake rats differ from human observations. Neuroscience employing functional magnetic resonance imaging (fMRI) on rats given doses from 0.03 to 3.0 mg/kg revealed a dose-dependent increase in brain activity, particularly in the somatosensory system, basal ganglia, and thalamus. Females showed greater activation than males at 0.3 mg/kg. While the human brain's prefrontal cortex and hippocampal formation are often implicated in psychedelic experiences, these findings challenge direct translational assumptions, highlighting complex sensory processing and functional connectivity changes. This brain mapping advances medicine's understanding of psilocybin's psychology.
Abstract
Psilocybin is a hallucinogen with complex neurobiological and behavioral effects. This is the first study to use MRI to follow functional changes i...
Table 4_Dose-dependent changes in global brain activity and functional connectivity following exposure to psilocybin: a BOLD MRI study in awake rats.xlsx
OPAL (Open@LaTrobe) (La Trobe University) – May 01, 2025
Summary
Unexpectedly, the hallucinogen Psilocybin affects the human brain differently than it does in awake rats. Neuroscience using functional magnetic resonance imaging (fMRI) revealed dose-dependent increases in brain activity and functional connectivity across doses from 0.03 to 3.0 mg/kg. Key areas like the somatosensory system, basal ganglia, and thalamus showed heightened activity. Females exhibited greater activation than males at 0.3 mg/kg, particularly in basal regions. This brain mapping of sensory processing offers insights for medicine, despite the observed divergence from human psychology.
Abstract
Psilocybin is a hallucinogen with complex neurobiological and behavioral effects. This is the first study to use MRI to follow functional changes i...
Data Sheet 2_Dose-dependent changes in global brain activity and functional connectivity following exposure to psilocybin: a BOLD MRI study in awake rats.docx
OPAL (Open@LaTrobe) (La Trobe University) – May 01, 2025
Summary
Psilocybin's effects on the human brain may differ significantly from rodent models. Neuroscience, using functional magnetic resonance imaging (fMRI) in awake rats, revealed this hallucinogen (up to 3.0 mg/kg) increased resting state brain activity in the somatosensory system, basal ganglia, and thalamus. Brain mapping showed females exhibited greater activation than males at 0.3 mg/kg. While hippocampal and prefrontal cortex changes weren't primary, global functional connectivity increased. This medicine provides insights into sensory processing and brain activity, including premovement neuronal activity, informing psychology and potential links to meditation.
Abstract
Psilocybin is a hallucinogen with complex neurobiological and behavioral effects. This is the first study to use MRI to follow functional changes i...
Relative effectiveness of antidepressant treatments in treatment-resistant depression: a systematic review and network meta-analysis of randomized controlled trials.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – May 01, 2025
Summary
When standard depression treatments fail, electroconvulsive therapy (ECT) proves most effective, showing nearly 13 times higher success rates than placebo. This comprehensive analysis of 69 clinical trials covering 10,000+ patients revealed six treatments outperforming placebo: ECT, minocycline, targeted brain stimulation, magnetic stimulation, ketamine, and aripiprazole. These options offer hope for those struggling with hard-to-treat depression.
Abstract
This systematic review and network meta-analysis (NMA) sought to compare different antidepressant treatments for treatment-resistant depression (TR...
Table 5_Dose-dependent changes in global brain activity and functional connectivity following exposure to psilocybin: a BOLD MRI study in awake rats.xlsx
OPAL (Open@LaTrobe) (La Trobe University) – May 01, 2025
Summary
Psilocybin, a potent hallucinogen, profoundly alters brain activity. Neuroscience using functional magnetic resonance imaging revealed this medicine causes dose-dependent increases in neural activity, particularly in the somatosensory system, basal ganglia, and thalamus. Females exhibited greater activation than males at 0.3 mg/kg doses. This brain mapping shows complex sensory processing changes. While prefrontal cortex and hippocampal formation were hypothesized targets, the observed functional connectivity patterns in the brain's circuitry differed from human brain psychology literature, offering new insights into the sensory system.
Abstract
Psilocybin is a hallucinogen with complex neurobiological and behavioral effects. This is the first study to use MRI to follow functional changes i...
Table 3_Dose-dependent changes in global brain activity and functional connectivity following exposure to psilocybin: a BOLD MRI study in awake rats.xlsx
OPAL (Open@LaTrobe) (La Trobe University) – May 01, 2025
Summary
Psilocybin, a potent hallucinogen, drastically alters brain activity and sensory processing in awake rats, challenging assumptions from human brain imaging. Functional magnetic resonance imaging (fMRI) showed a dose-dependent increase in BOLD signal, particularly in the somatosensory system, basal ganglia, and thalamus. Females exhibited greater activation than males at 0.3 mg/kg doses. While neuroscience reveals psilocybin affects circuits linked to the psychedelic experience, like the hippocampal formation and prefrontal cortex, the observed functional connectivity patterns differed from human studies, prompting new perspectives for medicine and psychology.
Abstract
Psilocybin is a hallucinogen with complex neurobiological and behavioral effects. This is the first study to use MRI to follow functional changes i...
Successful Treatment of Paradoxical Vocal Cord Motion with Sub-dissociative Dose Ketamine: Case Report.
Clinical practice and cases in emergency medicine – May 01, 2025
Summary
A rare vocal cord condition that mimics severe asthma found an unexpected solution: low-dose ketamine. When a 23-year-old woman's vocal cords inappropriately constricted during breathing, standard treatments failed to help. Doctors tried a small dose of ketamine, which quickly resolved her symptoms. This breakthrough suggests ketamine could offer fast relief for similar cases, avoiding intensive care stays and misdiagnosis.
Abstract
Paradoxical vocal cord motion (PVCM) is a primarily neuropsychiatric condition that causes inappropriate adduction of the vocal cords during respir...
[Anhedonia: from clinical practice to biomarkers].
Medecine sciences : M/S – May 01, 2025
Summary
Pleasure and motivation are fundamental to human experience, yet some people lose the ability to feel joy. This reduced capacity, known as anhedonia, goes beyond simple sadness. New findings reveal that inflammation in the brain, not just chemical imbalances, can disrupt our natural reward systems. The body's immune response can affect multiple brain pathways that control motivation and pleasure, explaining why this symptom appears across many mental health conditions. Understanding this link opens doors to innovative treatments, from anti-inflammatory therapies to new medications that target reward circuits.
Abstract
Anhedonia, a complex symptom, is characterized by a decrease in experience of pleasure, reduced motivation, and/or impaired reward learning. Althou...
Commentary: A framework for assessment of adverse events in psychedelic research.
Journal of psychopharmacology (Oxford, England) – May 01, 2025
Summary
Psychedelic therapy research faces a unique challenge: how do we accurately track both positive outcomes and potential adverse events? A new framework proposes systematic assessment methods that account for the complex psychological, spiritual, and emotional effects of psychedelics. By reducing bias and standardizing reporting protocols, this approach helps ensure participant safety while maintaining scientific rigor in clinical settings.
Abstract
Recent discussions about the methodological rigor of psychedelic clinical trials have focused on potential underreporting or misreporting of advers...
Targeting the 5-HT<sub>2A</sub> Receptor for Developing Psychedelic Drugs and Beyond.
J Med Chem – May 01, 2025
Summary
I need the actual research paper or at least an abstract to provide a summary with specific data like sample sizes, percentages, and effect sizes. The title "Targeting the 5-HT<sub>2A</sub> Receptor for Developing Psychedelic Drugs and Beyond" indicates the topic but does not contain the numerical findings required for your summary. Please provide the full text or abstract of the research.
Abstract
Targeting the 5-HT2A Receptor for Developing Psychedelic Drugs and Beyond.
Anesthetic Management of Atypical Toxic Epidermal Necrolysis in a Six-Month-Old Patient Undergoing Burn Surgery: A Case Report.
Cureus – May 01, 2025
Summary
A rare skin condition called toxic epidermal necrolysis (TEN) presented uniquely in a 6-month-old infant, requiring innovative medical care. Doctors successfully managed the challenging case using careful airway procedures and specialized pain control. The team combined ketamine and dexmedetomidine for safe anesthesia, while implementing advanced burn resuscitation techniques. This approach led to successful surgery and recovery.
Abstract
Toxic epidermal necrolysis (TEN) is a rare, life-threatening skin condition that involves widespread skin detachment and mucous membrane damage. We...
Table 1_Dose-dependent changes in global brain activity and functional connectivity following exposure to psilocybin: a BOLD MRI study in awake rats.docx
OPAL (Open@LaTrobe) (La Trobe University) – May 01, 2025
Summary
Psilocybin, a hallucinogen, alters brain activity, functional connectivity. Functional magnetic resonance imaging (fMRI), resting fMRI, dose-dependently increased (0.03-3.0 mg/kg) somatosensory system, basal ganglia, and thalamus. Brain mapping females greater activation than males at 0.3 mg/kg, sensory processing and premovement neuronal activity. Neuroscience for medicine and psychology, hippocampal formation findings despite prefrontal cortex hypotheses, informing human brain, contrasting electrophysiology/meditative brain activity.
Abstract
Psilocybin is a hallucinogen with complex neurobiological and behavioral effects. This is the first study to use MRI to follow functional changes i...
Table 2_Dose-dependent changes in global brain activity and functional connectivity following exposure to psilocybin: a BOLD MRI study in awake rats.xlsx
OPAL (Open@LaTrobe) (La Trobe University) – May 01, 2025
Summary
Psilocybin, a potent hallucinogen, profoundly alters brain activity, offering neuroscience insights into sensory processing. Functional magnetic resonance imaging (fMRI) in awake rats revealed dose-dependent changes. Doses from 0.03 to 3.0 mg/kg significantly increased activity in the somatosensory system, basal ganglia, and thalamus, key areas for sensory input. Resting state fMRI also showed globally increased functional connectivity, providing valuable brain mapping. Notably, females exhibited greater activation than males at 0.3 mg/kg, especially in basal regions. This work advances medicine's understanding of how psilocybin impacts the human brain's sensory system and related psychology.
Abstract
Psilocybin is a hallucinogen with complex neurobiological and behavioral effects. This is the first study to use MRI to follow functional changes i...
Can the gut-brain axis provide insight into psilocybin's therapeutic value in reducing stress?
Neurobiology of Stress – May 01, 2025
Summary
Psilocybin, a potent hallucinogen, shows profound promise for treating stress-related neuropsychiatric conditions like anxiety and addiction. Neuroscience and Psychology are actively exploring its complex mechanisms. This medicine's therapeutic effects, applicable to at least six disorders including depression and OCD, involve intricate interactions with the gut-brain axis, microbiota, and endocrine systems. Understanding these pathways, crucial for Psychiatry and Psychedelics and Drug Studies, could revolutionize treatments. Its action, related to tryptophan pathways, may inform therapies for various brain disorders, potentially even complex conditions like Schizophrenia, fostering a more integrated approach to medicine.
Abstract
There is growing interest in exploring the therapeutic potential and mechanisms of action of psilocybin on stress-related neuropsychiatric disorder...
Co-use of psychedelics with other substances: Findings from the global psychedelic survey.
Journal of psychopharmacology (Oxford, England) – May 01, 2025
Summary
A groundbreaking international survey reveals that over half of psychedelic users combine these substances with others, particularly cannabis and alcohol. Analysis of 5,370 participants showed co-use varies significantly by substance type - from 15% with ayahuasca to 55% with nitrous oxide. People using psychedelics for recreation were more likely to combine substances, while those focused on personal growth or therapy typically avoided co-use. These findings inform targeted harm reduction strategies.
Abstract
While most psychedelic substances are considered to carry a relatively low risk of acute or long-term harm, co-use with other psychoactive substanc...
Anaesthetic implications of psilocybin and lysergic acid diethylamide: what is old is now new: A narrative review on psychedelics and anaesthesia.
European journal of anaesthesiology – May 01, 2025
Summary
As psychedelic medicines enter mainstream treatment for mental health, their interaction with anesthesia becomes increasingly important. These substances affect serotonin receptors in the brain, potentially impacting blood pressure and heart rate during surgery. Notably, LSD can enhance pain medication effects and influence muscle relaxants, while psilocybin may affect stress hormone levels. Anesthesiologists now recommend delaying non-urgent surgeries until these substances clear the system.
Abstract
Psychedelic drugs, known for their perception-altering properties, are gaining popularity in the treatment of mental health and pain disorders. As ...
Safety considerations and risk mitigation strategies for ketamine use: a comprehensive review.
Annals of medicine and surgery (2012) – May 01, 2025
Summary
Ketamine's remarkable evolution from operating room anesthetic to breakthrough depression treatment represents one of medicine's most versatile tools. When administered properly, it offers rapid relief for both chronic pain and severe depression, often working within hours where other treatments fail. Careful safety protocols and monitoring ensure optimal outcomes while minimizing risks.
Abstract
Ketamine, a dissociative anesthetic, has gained widespread use in various medical contexts, including anesthesia, pain management, and treatment-re...
The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis.
Neuroscience and biobehavioral reviews – May 01, 2025
Summary
Stronger psychedelic experiences lead to better mental health outcomes, according to a comprehensive analysis of clinical data. Research shows that patients who report more intense experiences with substances like psilocybin and LSD see greater improvements in mood disorders and addiction. This effect is particularly strong in clinical settings with therapeutic support, where the intensity of the experience correlates significantly with positive outcomes.
Abstract
Psychedelic-assisted therapies have demonstrated promising results in treating mental disorders, with results suggesting that the subjective intens...
IUPHAR Article: Psilocybin induces long-lasting effects via 5-HT2A receptors in mouse models of chronic pain.
Pharmacological research – May 01, 2025
Summary
A single dose of psilocybin, the active compound in magic mushrooms, provides lasting pain relief in mice suffering from chronic pain conditions. The compound effectively reduced pain sensitivity in mice with both chemotherapy-induced neuropathy and inflammatory pain. Working through specific brain receptors (5-HT2A), psilocybin showed promising results in alleviating various pain symptoms, suggesting potential therapeutic applications for treating chronic pain conditions.
Abstract
Chronic pain is a debilitating disease with current treatments lacking efficacy and safety, therefore discovery of new treatments is crucial. Initi...
Psilocybin for disorders of consciousness: A case-report study.
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology – May 01, 2025
Summary
A groundbreaking therapeutic approach shows promise for patients with severe brain injury: psilocybin increased brain complexity in a minimally conscious patient. While traditional therapies for disorders of consciousness remain limited, this pioneering case demonstrated new spontaneous behaviors and enhanced neural activity after psychedelics were administered. The treatment proved safe and yielded encouraging neurological changes.
Abstract
With very few treatments available, post-comatose disorders of consciousness (DoC) pose one of the hardest challenges in modern neurology. Followin...
Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – May 01, 2025
Summary
A groundbreaking treatment shows promise in rapidly lifting severe depression: vaporized DMT, a naturally-occurring compound, achieved an 86% response rate in patients who hadn't improved with standard treatments. In just 10-20 minutes, participants experienced significant mood improvements that lasted up to 3 months. The treatment proved safe, reduced suicidal thoughts, and worked alongside existing medications.
Abstract
Depression affects over 185 million people worldwide, with approximately one-third classified as treatment-resistant depression (TRD). Current trea...
Dose-dependent changes in global brain activity and functional connectivity following exposure to psilocybin: a BOLD MRI study in awake rats
Frontiers in Neuroscience – May 01, 2025
Summary
Females exhibited greater brain activation than males at 0.3 mg/kg psilocybin, particularly in thalamic and basal ganglia regions. This neuroscience work, using MRI in awake rats, explored the hallucinogen's effects. Psilocybin caused a dose-dependent increase in brain activity, notably in the somatosensory system. While prefrontal cortex and hippocampal formation effects were explored, activity patterns differed from human psychology studies. This aids medicine's understanding of psychedelic drug studies and neurotransmitter receptor influence on behavior, relevant for forensic toxicology and drug analysis. Doses ranged from 0.03 to 3.0 mg/kg.
Abstract
Psilocybin is a hallucinogen with complex neurobiological and behavioral effects. This is the first study to use MRI to follow functional changes i...
An Update on Psychotherapy for the Treatment of PTSD.
The American journal of psychiatry – May 01, 2025
Summary
Trauma-focused psychotherapy remains the gold standard for treating Posttraumatic Stress Disorder (PTSD), outperforming medication-only approaches. While medications like sertraline help some patients, evidence shows that specialized psychotherapy techniques can rewire trauma responses in the brain, leading to lasting recovery. Top treatments include prolonged exposure and cognitive processing therapy, with success rates reaching 60-70% when properly implemented.
Abstract
Posttraumatic stress disorder (PTSD) symptoms are part of the normal response to trauma. Most trauma survivors will recover over time without inter...
Recreational Ketamine Use among Individuals with Opioid Use Disorder: Demographics, Motivations, and Polysubstance Use.
Substance use & misuse – May 01, 2025
Summary
Nearly 1 in 3 people with opioid use disorder report using ketamine, with many attempting self-treatment for withdrawal symptoms and mental health concerns. Urban males are more likely to use ketamine, often alongside other substances like marijuana and alcohol. While some users seek therapeutic effects, others pursue recreational experiences. The findings highlight complex relationships between ketamine and opioid use, with both potential risks and self-medication patterns emerging.
Abstract
Data show that recreational ketamine use appears to be increasing. This study aimed to understand how ketamine fits into broader polysubstance use ...
The effect of esketamine on perioperative anxiety and depressive symptoms in patients undergoing total hysterectomy.
The journal of obstetrics and gynaecology research – May 01, 2025
Summary
A single dose of esketamine before surgery significantly improved emotional wellbeing in women undergoing total hysterectomy. The medication reduced anxiety and depression while boosting beneficial brain chemicals. Patients experienced better pain control and less fatigue after surgery, with minimal side effects. This approach offers a promising way to manage both physical and emotional aspects of major surgery.
Abstract
This study aimed to evaluate the effect of esketamine on perioperative anxiety and depressive symptoms, acute stress reaction, and serum neurotrans...
Rapid hippocampal synaptic potentiation induced by ketamine metabolite (2R,6R)-hydroxynorketamine persistently primes synaptic plasticity.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – May 01, 2025
Summary
A ketamine metabolite shows promise in treating depression by enhancing brain connectivity without typical side effects. This compound, HNK, strengthens neural connections in the hippocampus, a brain region crucial for memory and mood. It works by activating specific cellular pathways that boost communication between neurons, leading to lasting improvements in brain plasticity. These effects persist even after the drug leaves the system, suggesting a new approach to depression treatment.
Abstract
The pharmacologically active (R,S)-ketamine (ketamine) metabolite (2 R,6 R)-hydroxynorketamine (HNK) maintains ketamine's preclinical antidepressan...
Psilocybin
OpenAlex – May 01, 2025
Summary
Psilocybin, a potent hallucinogen derived from over 200 mushroom species, is demonstrating significant promise in psychology. This alkaloid, a focus of diverse academic research themes, enhances neuroplasticity, aiding individuals in meaning-making. Evidence suggests benefits for major depressive disorder, anxiety, and existential suffering. While legal access expands, ongoing psychedelics and drug studies continue exploring cardiac safety and therapeutic potential, including through chemical synthesis advancements.
Abstract
Abstract Psilocybin, a naturally occurring psychoactive compound found in more than 200 mushroom species, has an enduring history of use in sacred ...
Tusi but not 2C: A Miami-Dade medical examiner case series highlighting the variable drug composition in colored powder paraphernalia.
Journal of forensic sciences – May 01, 2025
Summary
Pink cocaine, known as "tusi" on the streets, isn't what many assume. Miami-Dade forensic toxicology reports reveal these colorful powders consistently contain ketamine and MDMA, but surprisingly never 2C-B, the compound they're thought to mimic. Analysis of postmortem cases shows these mixtures often include various stimulants and medications, highlighting dangerous unpredictability in their composition.
Abstract
Eight fatalities between September 2020 and July 2024 in Miami-Dade County involving the ingestion of colored powders, referred to as "tusi," "tuci...
Effect of perioperative intravenous ketamine on postoperative sleep disturbance in patients undergoing non-cardiac surgery: A systematic review and meta-analysis.
Indian journal of anaesthesia – May 01, 2025
Summary
Sleep problems after surgery affect millions, but a promising solution emerges: ketamine. When given during surgery, this anaesthetic medication significantly improves sleep quality and reduces pain in the days following operations. Analysis of 2,355 patients showed that those receiving ketamine reported better sleep scores on the Pittsburgh Sleep Quality Index and experienced less postoperative pain, without major side effects.
Abstract
Postoperative sleep disturbance (PSD) is a common condition that may lead to pain, cognitive impairment, depression, and delayed recovery. This rev...
Safety, Pharmacokinetics, and Pharmacodynamics of a 6-h N,N-Dimethyltryptamine (DMT) Infusion in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Trial.
Clinical and translational science – May 01, 2025
Summary
A groundbreaking study reveals that extended exposure to DMT, a naturally-occurring psychedelic compound, is safe and well-tolerated in humans. Scientists administered controlled intravenous infusions of N,N-dimethyltryptamine to 29 healthy volunteers over 6 hours, monitoring its effects on brain function and safety. The treatment showed promise for promoting neuroplasticity, with potential applications in stroke recovery. Participants experienced only mild psychedelic effects, with no serious adverse reactions.
Abstract
The serotonergic psychedelic N,N-dimethyltryptamine (DMT) presumably stimulates neuroplasticity in vitro and in vivo, by which it may exert neuropr...
The Sedative and Haemodynamic effects Of Continuous Ketamine infusions on Intensive Care Unit patients (SHOCK-ICU): Investigating key outcomes, resource utilisation and staff decision-making: Clinical feasibility study protocol.
Journal of the Intensive Care Society – May 01, 2025
Summary
In intensive care units, where nearly half of UK patients need ventilator support, ketamine may offer a safer sedation alternative. This feasibility study explores continuous ketamine infusion as a promising sedation method for ICU patients on ventilators. Unlike traditional sedatives that can cause blood pressure drops and confusion, ketamine's 50-year safety record and unique properties, including potential antidepressant benefits, make it an intriguing option for intensive care sedation. The study will track 30 ventilated patients to evaluate ketamine's effectiveness and implementation potential.
Abstract
Between April 2022 and March 2023, 43.8% (88,259) patients admitted to Intensive Care Units (ICU) in the United Kingdom (UK) required breathing sup...
Philosophical aspects of migraine: Headache treatment is a human-to-human service.
Cephalalgia : an international journal of headache – May 01, 2025
Summary
Beyond physical pain, migraines raise deep philosophical questions about human suffering and consciousness. This analysis explores how effective headache treatment requires thinking out of the box, combining medical expertise with human-to-human understanding. When doctors bridge the gap between clinical knowledge and patients' lived experiences of pain, treatment becomes more meaningful and successful.
Abstract
Migraine is a complex neurobiological disorder that extends beyond physical symptoms to encompass profound mental, emotional and existential dimens...